-transparent.png){kind=logo}
A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day). The plasma concentrations of procainamide and N-acetyl procainamide were at subtherapeutic levels. Discontinuation of procainamide led to complete recovery. A bone marrow aspiration showed slight hypoplasia with normocellular marrow. Lupus erythematosus (LE) and antinuclear antibody (ANA) tests were negative. The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed. Precautionary measures for the early recognition of this grave hazard in exposed patients are advocated. The physician should be aware of this complication before in initiating treatment with this drug.
H Abe, and
H Suzuka, and
H Tasaki, and
A Kuroiwa
January 1976,
British heart journal,
H Abe, and
H Suzuka, and
H Tasaki, and
A Kuroiwa
November 1984,
Canadian Medical Association journal,
H Abe, and
H Suzuka, and
H Tasaki, and
A Kuroiwa
March 1975,
Current therapeutic research, clinical and experimental,
H Abe, and
H Suzuka, and
H Tasaki, and
A Kuroiwa
November 1975,
Current therapeutic research, clinical and experimental,
H Abe, and
H Suzuka, and
H Tasaki, and
A Kuroiwa
April 1985,
Archives of internal medicine,
H Abe, and
H Suzuka, and
H Tasaki, and
A Kuroiwa
June 1984,
Drug intelligence & clinical pharmacy,
H Abe, and
H Suzuka, and
H Tasaki, and
A Kuroiwa
September 1984,
Annals of internal medicine,
H Abe, and
H Suzuka, and
H Tasaki, and
A Kuroiwa
August 1978,
Scandinavian journal of haematology,
H Abe, and
H Suzuka, and
H Tasaki, and
A Kuroiwa
July 1987,
Clinical pharmacology and therapeutics,
H Abe, and
H Suzuka, and
H Tasaki, and
A Kuroiwa
March 1983,
Texas Heart Institute journal,
